Alivus Life Sciences Limited has informed the Exchange regarding a press release dated May 14, 2026, titled "Press Release of the Company for the fourth quarter and year ended March 31, 2026.".
ALIVUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alivus Life Sciences (formerly Glenmark Life Sciences) reported strong FY26 results with revenue from operations of Rs. 25,518 Mn, up 6.9% YoY. EBITDA grew 19.6% to Rs. 8,577 Mn with margins expanding 360 bps to 33.6%, exceeding the company's guided range of 30-32%. PAT stood at Rs. 5,645 Mn, growing 16.2% YoY with margins at 22.1%, up 180 bps. The company generated strong free cash flow of Rs. 2,590 Mn and ended with cash and equivalents of Rs. 7,824 Mn, maintaining a debt-free balance sheet. The CDMO business delivered an 18% YoY turnaround in H2, while GPL business de-grew 4.9%.
Strong operational performance with significant margin expansion signals improved profitability and cost efficiency. The company's debt-free status and robust cash generation provide financial flexibility for growth investments in new R&D facilities and expanded manufacturing capacity.